Diffusion-weighted imaging performed with MRI for breast cancer screening may reduce the number of preventable breast biopsies.
Diffusion-weighted imaging, which uses water diffusion measurements, performed with MRI for breast cancer screening may reduce the number of preventable breast biopsies, according to a study published online in the journal Radiology.
The increasing use of dynamic contrast-enhanced MRI (DCE-MRI) for breast cancer screening has resulted in a substantial number of false-positive findings. These false positives often resulted in women having to undergo unnecessary breast biopsies. Researchers found that the introduction of diffusion-weighted imaging (DWI) to DCE-MRI reduces the incidence of false-positives and the procedure does not require any additional contrast or hardware. Further, it only adds a few extra minutes to the exam.
“DWI has been used mostly in neurological applications, but it’s been studied more recently in breast imaging,” said Savannah C. Partridge, PhD, a research associate professor at the University of Washington, Seattle Cancer Care Alliance.
Researchers evaluated 175 non-malignant breast lesions in 165 women to assess the DWI in conjunction with MRI in distinguishing between benign and malignant breast tumors. The DWI calculates the apparent diffusion coefficient (ADC), a measure of how water moves through tissues.
Normal breast tissue has a high ADC because water moves through it relatively freely, while most cancers have a lower ADC because the cells are more tightly packed, restricting water movement. Based on ADC values above a previously determined diagnostic threshold, DWI successfully characterized 81 lesions (46 percent) that had been falsely identified as on DCE-MRI as benign.
The most prevalent lesion subtypes with mean ADCs above the threshold were fibroadenoma, focal fibrosis, normal tissue, apocrine metaplasia, usual ductal hyperplasia, and inflammation.
Atypical ductal hyperplasia was the most common lesion subtype with ADC below the threshold. High-risk lesions (atypical ductal hyperplasia and lobular neoplasia) showed significantly lower ADCs than other benign lesions and were the most common lesions with ADCs below the threshold.
“We were excited to see the number of false positives that could be reduced through this approach,” said Partridge in a press release. “DWI gives us extra microstructural information to distinguish among lesions. We can use ADC values to draw a cutoff above which we might not need to do a biopsy.”
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.